Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal.
Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal.
Res Vet Sci. 2014 Feb;96(1):79-85. doi: 10.1016/j.rvsc.2013.11.007. Epub 2013 Nov 25.
Recombinant-Feline Interferon-Omega (rFeIFN-ω) is an immune-modulator licensed for use subcutaneously in Feline Immunodeficiency virus (FIV) therapy. Despite oral protocols have been suggested, little is known about such use in FIV-infected cats. This study aimed to evaluate the clinical improvement, laboratory findings, concurrent viral excretion and acute phase proteins (APPs) in naturally FIV-infected cats under oral rFeIFN-ω therapy (0.1 MU/cat rFeIFN-ω PO, SID, 90 days). 11 FIV-positive cats were treated with oral rFeIFN-ω (PO Group). Results were compared to previous data from 7 FIV-positive cats treated with the subcutaneous licensed protocol (SC Group). Initial clinical scores were similar in both groups. Independently of the protocol, rFeIFN-ω induced a significant clinical improvement of treated cats. Concurrent viral excretion and APP's variation were not significant in the PO Group. Oral rFeIFN-ω can be an effective alternative therapy for FIV-infected cats, being also an option for treatment follow-up in cats submitted to the licensed protocol.
重组猫干扰素-ω（rFeIFN-ω）是一种免疫调节剂，获准皮下用于治疗猫免疫缺陷病毒（FIV）。尽管已经提出了口服方案，但对于感染 FIV 的猫的这种使用知之甚少。本研究旨在评估口服 rFeIFN-ω 治疗（0.1 MU/只猫 rFeIFN-ω PO，每天 1 次，90 天）对自然感染 FIV 的猫的临床改善、实验室发现、并发病毒排出和急性期蛋白（APPs）的影响。11 只 FIV 阳性猫接受了口服 rFeIFN-ω 治疗（PO 组）。结果与之前接受皮下许可方案治疗的 7 只 FIV 阳性猫的先前数据（SC 组）进行了比较。两组的初始临床评分相似。无论采用哪种方案，rFeIFN-ω 都能显著改善治疗猫的临床症状。PO 组的并发病毒排出和 APP 变化不显著。口服 rFeIFN-ω 可能是感染 FIV 的猫的有效替代治疗方法，也可作为已接受许可方案治疗的猫的治疗随访选择。
